Add time:08/26/2019         Source:sciencedirect.com

BackgroundControversy still exists that whether Clopidogrel (cas 113665-84-2) should add proton pump inhibitors (PPIs) in patients with coronary heart disease after percutaneous coronary intervention (PCI). The aim of this study was to evaluate the efficacy and safety of clopidogrel added proton pump inhibitors (PPIs) vs. clopidogrel for the treatment of patients with coronary heart disease after percutaneous coronary intervention (PCI).

We also recommend Trading Suppliers and Manufacturers of Clopidogrel (cas 113665-84-2). Pls Click Website Link as below: cas 113665-84-2 suppliers